Steatosis in hepatitis C: The missing link to metabolic abnormalities?

American Journal of Gastroenterology

Volumn 101, Issue 11, 2006, Pages 2616-2618

  Zein, Nizar N ^a   Poterucha, John J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; DRUG RESEARCH; FATTY LIVER; HEPATITIS C; HUMAN; LIVER INJURY; MEDICAL RESEARCH; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; REVIEW; SCREENING; STEATOSIS; UNITED STATES;

ADULT; CHILD; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS;

EID: 33750516941     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00909.x     Document Type: Review

References (21)

1. Guido M, Bortolotti F. Liver steatosis in children with chronic hepatitis C. Am J Gastroenterol 2006;2611-5.
2. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
3. Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation. J Gastroenterol Hepatol 2001;16:190-5.
4. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
5. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
6. Zein NN, Abdulkarim AS, Wiesner RH, et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000;32:209-17.
7. Zein CO, Levy C, Basu A, et al. Chronic hepatitis C and type II diabetes mellitus: A prospective cross-sectional study. Am J Gastroenterol 2005;100:48-55.
8. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology 2001;33:1554.
9. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003;38:50-6.
10. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8.
11. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-97.
12. Romero-Gomez M, Del MV, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
13. Cesario K, Khandwala F, Carey WD, et al. Impact of obesity on degree of liver disease and response to therapy in patients with chronic hepatitis C. Gastroenterology 2005;128:746.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
15. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
17. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
18. Lam NP, Pitrak D, Speralakis R, et al. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997;42:178-85.
19. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
20. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-9.
21. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.